{"id":5019,"date":"2026-07-05T01:00:34","date_gmt":"2026-07-05T01:00:34","guid":{"rendered":"https:\/\/miyodamachine.com\/?p=5019"},"modified":"2026-07-01T04:06:36","modified_gmt":"2026-07-01T04:06:36","slug":"injection-vs-extrusion-tube-manufacturing","status":"publish","type":"post","link":"https:\/\/miyodamachine.com\/fr\/injection-vs-extrusion-tube-manufacturing\/","title":{"rendered":"Injection vs. Extrusion: Which Tube Method Wins?"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5019\" class=\"elementor elementor-5019\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ec0f356 e-flex e-con-boxed e-con e-parent\" data-id=\"ec0f356\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7ec1514 elementor-widget elementor-widget-text-editor\" data-id=\"7ec1514\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<!-- ============ INTRODUCTION ============ -->\n<div class=\"article-intro-box\"><strong>The decision between injection molding and extrusion is one of the most consequential choices a tube manufacturer can make<\/strong> \u2014 and it&#8217;s rarely as simple as picking the faster or cheaper option. Your choice will determine not just your per-unit cost today, but your ability to launch new designs, scale volume, meet regulatory requirements, and serve premium versus mass-market clients five years from now. This guide gives you the technical, financial, and operational intelligence to make that decision with confidence \u2014 whether you&#8217;re producing toothpaste tubes by the million, niche dermatological creams in short runs, or pharmaceutical ointments under strict GMP (Good Manufacturing Practice) conditions.<\/div>\n<img decoding=\"async\" class=\"article-img\" src=\"https:\/\/images.unsplash.com\/photo-1611532736597-de2d4265fba3?w=1200&amp;q=80\" alt=\"Cosmetic and pharmaceutical soft tube packaging production line in a manufacturing facility\" \/>\n<p class=\"article-img-caption\">Modern soft tube packaging production lines serve cosmetics, oral care, and pharmaceutical markets \u2014 with manufacturing method selection directly impacting cost, quality, and compliance outcomes.<\/p>\n<!-- ============ UNDERSTANDING INJECTION MOLDING ============ -->\n<h2>Understanding Injection Molding for Tube Manufacturing<\/h2>\n<h3>How Injection Molding Works: The Technical Process<\/h3>\nInjection molding in the tube context refers to a <strong>cycle-based manufacturing process<\/strong> where molten thermoplastic material is injected under high pressure into a precisely engineered closed mold cavity. Unlike a continuous process, each cycle produces a discrete, fully formed component \u2014 most commonly the <em>tube shoulder and head assembly<\/em> in soft tube production. The extrusion process forms the tube body (the sleeve), while injection molding forms the structurally complex shoulder, orifice, and neck that define a tube&#8217;s functionality and brand identity. Understanding this distinction is critical: in most cosmetic and pharmaceutical tube production lines, both methods are actually used in combination, not as straight alternatives to each other.\n<h4>The Step-by-Step Injection Cycle Explained<\/h4>\n<ol class=\"process-steps\">\n \t<li><strong>Clamping:<\/strong> The mold&#8217;s two halves are clamped shut by the machine&#8217;s hydraulic or electric clamping unit, generating pressures of 1,000\u20135,000 tonnes to withstand the force of material injection.<\/li>\n \t<li><strong>Material Injection:<\/strong> Thermoplastic pellets (typically HDPE, LDPE, or PP) are fed from a hopper into a heated barrel where a reciprocating screw melts and homogenizes the material. The screw then advances, injecting molten plastic into the mold at pressures of 700\u20131,500 bar (10,000\u201321,750 PSI).<\/li>\n \t<li><strong>Cooling &amp; Solidification:<\/strong> The injected material cools and solidifies within the mold, conforming precisely to the cavity geometry. Cooling typically takes 5\u201330 seconds depending on wall thickness and material.<\/li>\n \t<li><strong>Mold Opening &amp; Ejection:<\/strong> Ejector pins push the solidified part from the mold. On tube shoulder machines, this yields a formed shoulder\/head assembly ready for attachment to the extruded tube body.<\/li>\n \t<li><strong>Cycle Reset:<\/strong> The mold closes and the sequence repeats. High-speed tube shoulder injection machines achieve <strong>80\u2013120 parts per minute<\/strong> in commercial production.<\/li>\n<\/ol>\n<div class=\"glossary-box\">\n<h3>\ud83d\udcd8 Key Terms: Injection Molding<\/h3>\n<dl>\n \t<dt>Clamping Force (tonnes)<\/dt>\n \t<dd>The force applied to keep the mold halves closed during injection. Higher viscosity materials and larger part areas require greater clamping force to prevent flash \u2014 material escaping at the mold parting line.<\/dd>\n \t<dt>Shot Size (cm\u00b3)<\/dt>\n \t<dd>The volume of molten material injected per cycle. For tube shoulder components, shot sizes are typically small (5\u201350 cm\u00b3), enabling fast cycle times.<\/dd>\n \t<dt>Cooling Time<\/dt>\n \t<dd>The portion of the cycle where the injected material solidifies. It represents 60\u201380% of total cycle time in most applications \u2014 reducing it through optimized cooling channel design is the primary lever for improving throughput.<\/dd>\n \t<dt>Flash<\/dt>\n \t<dd>Thin film of excess plastic that escapes between mold halves during injection. A quality defect that requires manual trimming, adding labor cost and creating material waste.<\/dd>\n<\/dl>\n<\/div>\n<h4>Key Equipment Components and Their Functions<\/h4>\nA tube shoulder injection molding machine integrates several subsystems. The <strong>injection unit<\/strong> (barrel, screw, and nozzle) plasticizes raw material and delivers it to the mold. The <strong>clamping unit<\/strong> opens, closes, and locks the mold with sufficient force. The <strong>mold tool<\/strong> itself \u2014 a precision-machined steel cavity set \u2014 defines the shoulder geometry and is the primary driver of both part quality and capital cost. Modern machines use <strong>servo-electric drives<\/strong> rather than purely hydraulic systems, offering 20\u201330% energy savings and significantly tighter repeatability across millions of cycles.\n<h3>Advantages of Injection Molding Technology<\/h3>\n<h4>Superior Product Quality and Consistency<\/h4>\nInjection molding delivers wall thickness precision to within <strong>\u00b10.05mm<\/strong> on well-maintained tooling \u2014 a level of dimensional consistency that is nearly impossible to match with extrusion alone on complex 3D geometries like tube shoulders. For a premium skincare brand whose customer associates squeeze feel and cap snap-fit with product quality, this precision translates directly to perceived brand value. Pharmaceutical clients operating under <a href=\"https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/pharmaceutical-inspections-and-compliance\" target=\"_blank\" rel=\"noopener\">FDA CGMP (Current Good Manufacturing Practice)<\/a> standards require documented dimensional consistency and material traceability that injection molding processes are specifically engineered to provide.\n<h4>Design Flexibility and Customization Capabilities<\/h4>\nThe mold cavity is, in essence, a 3D template with unlimited geometric freedom. Injection molding can produce tube shoulders with <strong>integrated flip-top closures, tamper-evident bands, multi-orifice tips, child-resistant mechanisms, and decorative surface textures<\/strong> \u2014 all in a single cycle, with no secondary operations. A cosmetic brand launching a prestige face cream tube with an embossed logo cap and a tapered oval shoulder can achieve that design through injection molding in a way that extrusion simply cannot replicate. For contract manufacturers serving multiple premium brands, this flexibility is a meaningful competitive differentiator.\n\n<img decoding=\"async\" class=\"article-img\" src=\"https:\/\/images.pexels.com\/photos\/3373736\/pexels-photo-3373736.jpeg?w=1200&amp;q=80\" alt=\"Premium cosmetic tube packaging with injection molded shoulder and cap featuring intricate design detail\" \/>\n<p class=\"article-img-caption\">Injection molding enables complex tube shoulder geometries, decorative surface textures, and integrated closure features that extrusion alone cannot achieve \u2014 a key advantage for premium cosmetic and pharmaceutical packaging.<\/p>\n\n<h3>Limitations and Challenges of Injection Molding<\/h3>\n<h4>Higher Initial Capital Investment<\/h4>\nA production-ready injection mold for a standard tube shoulder typically costs between <strong>$15,000 and $80,000<\/strong> depending on cavity count, steel grade, and geometric complexity. A multi-cavity mold (8\u201316 cavities) for high-volume production can exceed <strong>$150,000<\/strong> before the machine investment. Compare this to extrusion dies, which typically range from <strong>$3,000 to $15,000<\/strong> \u2014 a 5\u201310\u00d7 difference. For a brand testing a new product line at 50,000 units annually, that tooling cost alone can make injection molding economically unjustifiable until volumes scale.\n<h4>Longer Setup Times and Mold Development Costs<\/h4>\nMold development from final design approval to first production-quality sample typically takes <strong>8\u201316 weeks<\/strong> for a standard tube shoulder tool, and 16\u201324 weeks for a complex multi-feature mold. Every design change after steel is cut adds both cost (typically $2,000\u2013$15,000 per major modification) and time. For brands operating in fast-moving beauty markets where a product launch window is measured in months, not quarters, this lead time can represent a genuine strategic risk.\n\n<!-- ============ EXTRUSION SECTION ============ -->\n<h2>Exploring Extrusion Methods in Tube Production<\/h2>\n<h3>How Extrusion Molding Works: The Technical Foundation<\/h3>\nExtrusion is a <strong>continuous manufacturing process<\/strong> where thermoplastic material is melted and forced through a shaped die to produce a continuous tube profile. Unlike injection molding&#8217;s discrete cycles, extrusion runs uninterrupted \u2014 making it the dominant method for producing the cylindrical tube body (sleeve) in soft tube packaging. The extruded tube body is then cut to length, and a separately injection-molded or compression-molded shoulder is attached in a downstream heading\/shoulder operation. In this architecture, extrusion and injection molding are <em>complementary<\/em>, not interchangeable \u2014 each performing the task it&#8217;s mechanically best suited for.\n<h4>Continuous Extrusion Process and Material Flow<\/h4>\nRaw thermoplastic pellets are fed from a hopper into a heated barrel containing a rotating screw. As the material travels along the barrel, it progressively melts through <strong>conduction from the barrel walls and frictional shear heat<\/strong> from the screw. Fully plasticized material is then forced through a precision die head. In multi-layer cosmetic tube production \u2014 which is standard for barrier-performance applications \u2014 <strong>co-extrusion die heads combine 3, 5, or 6 separate material streams simultaneously<\/strong>, forming a tube with distinct functional layers (e.g., LDPE\/TIE\/EVOH\/TIE\/LDPE) in a single pass. Systems like those built by <a href=\"https:\/\/miyodamachine.com\/fr\/produits\/machine-dextrusion-de-tubes\/\" target=\"_blank\" rel=\"noopener\">Miyoda Packaging Machinery&#8217;s tube extrusion line<\/a> achieve production speeds of 10\u201315 meters per minute with PLC control and laser diameter monitoring for real-time quality management.\n<h4>Die Design and Tube Formation Mechanisms<\/h4>\nThe extrusion die is the precision heart of the process. It must distribute melt flow uniformly around its circumference \u2014 any imbalance produces wall thickness variation that results in weak spots or dispensing inconsistency. <strong>Spiral mandrel dies<\/strong> are the current standard for cosmetic tube extrusion, using helical melt channels that eliminate weld lines (the streaks that occur when melt streams rejoin after splitting around a mandrel). After leaving the die, the hot tube is pulled through a <strong>vacuum sizing sleeve and water cooling bath<\/strong> that sets its external diameter to tolerance \u2014 typically \u00b10.1mm on commercial lines.\n<div class=\"youtube-embed\"><iframe title=\"Cosmetic Tube Manufacturing Process Step by Step \u2014 Extruded Plastic Tube Production\" src=\"https:\/\/www.youtube.com\/embed\/I0F-rbCk0Ug\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/div>\n<p class=\"youtube-caption\">Watch the step-by-step cosmetic tube extrusion process \u2014 from raw PE pellets through co-extrusion, cooling, cutting, and heading \u2014 to understand exactly how a finished soft tube body is formed.<\/p>\n\n<h3>Key Advantages of Extrusion Technology<\/h3>\n<h4>Rapid Production Speeds and High Output Capacity<\/h4>\nA single extrusion line running at 12 meters per minute on a standard 35mm-diameter tube produces approximately <strong>2,400\u20133,600 tube bodies per hour<\/strong> after cutting \u2014 far exceeding the output of a single injection molding press on a comparable footprint. At commercial scale with two or three extrusion lines running in parallel, output can reach <strong>150,000\u2013300,000 tube bodies per 24-hour day<\/strong>. For high-volume applications \u2014 mass-market toothpaste, sunscreen, shampoo, and over-the-counter pharmaceutical creams \u2014 this throughput advantage is decisive.\n<h4>Lower Tooling Costs and Faster Time-to-Market<\/h4>\nExtrusion dies for standard tube diameters cost <strong>$3,000\u2013$12,000<\/strong>, compared to $15,000\u2013$80,000+ for injection molds producing equivalent tube shoulder components. More importantly, die lead times of <strong>6\u201310 weeks<\/strong> are shorter than mold development cycles, and a single die set produces consistent tube bodies regardless of batch size \u2014 unlike injection molding, where high cavity-count tools are needed to achieve economic efficiency at high volumes. For a new brand needing 200,000 toothpaste tubes in three months, extrusion&#8217;s tooling economics and timeline often make it the only viable path.\n\n<a title=\"Troubleshooting servo motion issues on a filling and sealing machine\" href=\"https:\/\/www.flickr.com\/photos\/204745097@N06\/55367719673\/in\/dateposted-public\/\" data-flickr-embed=\"true\"><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/live.staticflickr.com\/65535\/55367719673_c5d31d6052_b.jpg\" alt=\"Troubleshooting servo motion issues on a filling and sealing machine\" width=\"1024\" height=\"765\" \/><\/a><script async src=\"\/\/embedr.flickr.com\/assets\/client-code.js\" charset=\"utf-8\"><\/script>\n<p class=\"article-img-caption\">Extrusion&#8217;s continuous production architecture delivers the throughput volumes that mass-market toothpaste, sunscreen, and personal care brands depend on \u2014 at tooling costs 5\u201310\u00d7 lower than injection mold tooling.<\/p>\n\n<h3>Disadvantages and Operational Constraints<\/h3>\n<h4>Limited Design Customization Options<\/h4>\nExtrusion produces uniform, rotationally symmetric tube bodies. It cannot produce oval cross-sections, flat tubes with non-uniform wall distributions, or integrated surface features like embossed logos directly in the tube body wall. These design elements require secondary operations \u2014 <strong>offset printing, hot stamping, silk-screen printing, or shrink-sleeve labeling<\/strong> \u2014 that add process steps, cost, and potential quality control points. For brands where the tube itself is a design statement (think luxury skincare or pharmaceutical packaging where dosing accuracy indicators are molded into the tube wall), extrusion&#8217;s geometric limitations matter.\n<h4>Quality Control Challenges in High-Speed Production<\/h4>\nRunning at 10\u201315 meters per minute, an extrusion line can produce hundreds of meters of out-of-specification tube before manual inspection detects an issue \u2014 particularly with subtle defects like wall thickness drift or micro-layer delamination. This is why modern extrusion lines for cosmetic and pharmaceutical tubes invest heavily in <strong>in-line laser gauging, ultrasonic wall measurement, and automated rejection systems<\/strong>. A line without these controls operating at high speed for a pharmaceutical client can generate a significant scrap event before an alarm triggers. The monitoring technology adds cost, but for regulated applications it is non-negotiable.\n\n<!-- ============ COST COMPARISON ============ -->\n<h2>Cost Comparison: Total Cost of Ownership Analysis<\/h2>\n<h3>Initial Capital Equipment Investment<\/h3>\n<h4>Injection Molding Machine Costs and ROI Timeline<\/h4>\nA production-grade tube shoulder injection molding machine \u2014 including the machine press, automation handling, and a single mold tool \u2014 represents a capital investment of <strong>$150,000\u2013$300,000<\/strong> for a mid-range automatic system capable of 80\u2013120 shots per minute. The mold tool itself must be added for each new product SKU. At $30,000 per mold and 10 active SKUs, tooling alone adds $300,000. <strong>ROI timelines of 24\u201348 months<\/strong> are typical at production volumes of 500,000\u20132,000,000 tube shoulders per year, assuming competitive pricing and high utilization rates. Machines built with servo-electric drives (increasingly standard) offset energy operating costs and reduce ROI timelines by 15\u201325%.\n<h4>Extrusion Equipment Pricing and Budget Considerations<\/h4>\nA complete cosmetic tube extrusion line \u2014 extruder, co-extrusion die head, cooling system, haul-off, cutter, and winder \u2014 ranges from <strong>$120,000 for a basic single-layer system to $400,000+ for a 5-layer co-extrusion line<\/strong> with laser gauging and automated rejection. The higher investment in multi-layer capability is justified by the premium this technology commands in the market: 5-layer EVOH barrier tubes sell at 30\u201380% premiums over single-layer PE tubes of equivalent dimensions. <a href=\"https:\/\/miyodamachine.com\/fr\/product\/\" target=\"_blank\" rel=\"noopener\">Miyoda Packaging Machinery&#8217;s full tube production line range<\/a> covers both single-layer and multi-layer co-extrusion configurations for cosmetic, pharmaceutical, and oral care applications.\n<h3>Tooling and Mold Expenses<\/h3>\n<h4>Injection Mold Development and Maintenance Costs<\/h4>\nInjection molds for tube shoulder production are typically manufactured from <strong>P20 or H13 tool steel<\/strong>, with cavity surfaces hardened and polished to Class A standards. A single 4-cavity shoulder mold for a standard 35mm cosmetic tube costs approximately <strong>$25,000\u2013$45,000<\/strong>. This cost is amortized across the mold&#8217;s working life of <strong>500,000\u20131,000,000+ cycles<\/strong> with proper maintenance \u2014 yielding a tooling cost contribution of $0.025\u2013$0.090 per part. Annual mold maintenance (polishing, ejector pin replacement, cooling channel cleaning) typically adds <strong>$2,000\u2013$5,000 per tool per year<\/strong> to running costs.\n<h4>Extrusion Die Costs and Replacement Frequency<\/h4>\nExtrusion dies \u2014 particularly spiral mandrel multi-layer co-extrusion die heads \u2014 require less frequent replacement than injection molds under normal operating conditions. A well-maintained die head for a 5-layer cosmetic tube line has an operational life of <strong>5\u201310 years<\/strong>. However, die head cleaning (required when switching materials or colors) can take <strong>4\u20138 hours of downtime<\/strong>, and a damaged die tip from contaminated material can cost <strong>$5,000\u2013$20,000<\/strong> to repair or replace. Tooling costs per unit produced are therefore substantially lower than injection molds over any production horizon exceeding 500,000 units.\n<h3>Operational and Running Costs<\/h3>\n<h4>Energy Consumption and Utility Expenses<\/h4>\nInjection molding machines for tube shoulder production typically consume <strong>15\u201325 kW per operational cycle<\/strong>, with significant variation based on clamping force requirements and material type. Extrusion lines run continuously at <strong>20\u201340 kW depending on output speed and number of extruder layers<\/strong>. At high volumes, extrusion&#8217;s continuous operation yields better energy efficiency per unit produced \u2014 particularly on 24-hour production schedules where the thermal mass of the barrel system holds temperature with less energy than repeatedly cycling an injection press between shots. Modern servo-electric drives on both machine types reduce energy consumption by 20\u201335% compared to hydraulic-only predecessors.\n<h4>Labor Requirements and Personnel Training Investments<\/h4>\nAn injection molding cell for tube shoulder production typically requires <strong>one skilled operator per shift per machine<\/strong> for setup, quality monitoring, and mold changes. Mold changeover training is complex \u2014 mishandled tool installation is a leading cause of mold damage in tube plants. Extrusion lines typically run with <strong>one operator per line per shift<\/strong>, but demand higher technical expertise in die head management, material changeovers, and real-time process adjustment. Investment in operator training for either technology runs <strong>$3,000\u2013$8,000 per trained technician<\/strong>, plus 60\u201390 days of supervised production to reach full competency.\n\n<!-- ============ COST COMPARISON TABLE ============ -->\n<div class=\"comparison-table-wrap\">\n<table class=\"comparison-table\">\n<thead>\n<tr>\n<th>Cost Category<\/th>\n<th>Injection Molding<\/th>\n<th>Extrusion<\/th>\n<th>Advantage<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Machine Capital Cost<\/td>\n<td>$150,000\u2013$300,000<\/td>\n<td>$120,000\u2013$400,000<\/td>\n<td class=\"highlight-blue\">Comparable<\/td>\n<\/tr>\n<tr>\n<td>Tooling per SKU<\/td>\n<td>$15,000\u2013$80,000<\/td>\n<td>$3,000\u2013$15,000<\/td>\n<td class=\"highlight-green\">Extrusion<\/td>\n<\/tr>\n<tr>\n<td>Tooling Lead Time<\/td>\n<td>8\u201316 weeks<\/td>\n<td>6\u201310 weeks<\/td>\n<td class=\"highlight-green\">Extrusion<\/td>\n<\/tr>\n<tr>\n<td>Tool Lifespan<\/td>\n<td>500K\u20131M+ cycles<\/td>\n<td>5\u201310 years<\/td>\n<td class=\"highlight-blue\">Comparable<\/td>\n<\/tr>\n<tr>\n<td>Energy per Unit (high vol.)<\/td>\n<td>Higher (cycle-based)<\/td>\n<td>Lower (continuous)<\/td>\n<td class=\"highlight-green\">Extrusion<\/td>\n<\/tr>\n<tr>\n<td>Material Waste Rate<\/td>\n<td>5\u201310%<\/td>\n<td>2\u20135%<\/td>\n<td class=\"highlight-green\">Extrusion<\/td>\n<\/tr>\n<tr>\n<td>Per-Unit Cost @ 100K units<\/td>\n<td>$0.15\u2013$0.35<\/td>\n<td>$0.20\u2013$0.40<\/td>\n<td class=\"highlight-blue\">Injection<\/td>\n<\/tr>\n<tr>\n<td>Per-Unit Cost @ 1M units<\/td>\n<td>$0.12\u2013$0.25<\/td>\n<td>$0.08\u2013$0.18<\/td>\n<td class=\"highlight-green\">Extrusion<\/td>\n<\/tr>\n<tr>\n<td>Design Complexity Capability<\/td>\n<td>High (3D geometries)<\/td>\n<td>Limited (linear profiles)<\/td>\n<td class=\"highlight-blue\">Injection<\/td>\n<\/tr>\n<tr>\n<td>Changeover Time (per SKU)<\/td>\n<td>2\u20134 hours<\/td>\n<td>4\u20138 hours<\/td>\n<td class=\"highlight-blue\">Injection<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"callout-box\">\n\nThe crossover point where extrusion becomes more cost-competitive than injection molding per unit typically occurs between <strong>500,000 and 1,000,000 units annually<\/strong>. Below this threshold, injection molding&#8217;s better flexibility and lower per-part waste often offset its higher tooling cost \u2014 especially for SKUs with complex shoulder designs that command premium pricing. Above this threshold, extrusion&#8217;s continuous throughput and lower material waste compound into a decisive cost advantage that grows with every million units produced.\n\n<\/div>\n<!-- ============ PRODUCTION SPEED ============ -->\n<h2>Production Speed and Capacity: Meeting Market Demands<\/h2>\n<h3>Cycle Times and Output Metrics<\/h3>\n<h4>Injection Molding Production Rates per Hour<\/h4>\nA high-speed tube shoulder injection molding machine running a 4-cavity mold at 80 shots per minute delivers <strong>320 shoulder components per minute, or approximately 19,200 per hour<\/strong>. A 16-cavity mold on the same press multiplies this to 76,800 components per hour \u2014 but requires a proportionally larger machine and a substantially more expensive mold tool. In practice, commercial tube shoulder injection operations run <strong>8\u201316 cavity molds at 60\u2013100 shots per minute<\/strong>, yielding 28,800\u201357,600 parts per hour per press. This represents meaningful output \u2014 but the cost and complexity of the tooling required to achieve it is a constant in the equation.\n<h4>Extrusion Speed Capabilities and Volume Potential<\/h4>\nA modern cosmetic tube extrusion line running at 12 meters per minute on 150mm-cut-length tubes produces <strong>80 cuts per minute \u2014 approximately 4,800 tube bodies per hour per line<\/strong>. Two parallel lines yield 9,600 per hour, and a facility with six lines achieves 28,800 tube bodies per hour with a relatively small equipment footprint and two operators per shift. At this scale, with 24-hour operation and 300 production days per year, a six-line extrusion facility can produce over <strong>200 million tube bodies annually<\/strong> \u2014 a volume that defines the economics of major toothpaste and personal care brands globally.\n<div class=\"inline-stat-grid\">\n<div class=\"stat-card blue\">\n<div class=\"stat-num\">80\u2013120<\/div>\n<div class=\"stat-label\">shots\/min \u2014 High-speed tube shoulder injection machine output<\/div>\n<\/div>\n<div class=\"stat-card green\">\n<div class=\"stat-num\">4,800+<\/div>\n<div class=\"stat-label\">tube bodies\/hour per single 5-layer co-extrusion line<\/div>\n<\/div>\n<div class=\"stat-card orange\">\n<div class=\"stat-num\">2\u20134 hrs<\/div>\n<div class=\"stat-label\">typical SKU changeover time for injection vs. 4\u20138 hrs for extrusion<\/div>\n<\/div>\n<\/div>\n<h3>Scalability Considerations for Growth<\/h3>\n<h4>Ramping Production with Injection Systems<\/h4>\nInjection molding scales through <strong>adding presses or increasing cavity counts<\/strong> \u2014 both of which require capital investment but can be staged strategically. A plant starting with two 8-cavity shoulder molds can add a third mold and press when volume justifies it, without disrupting existing production. The modularity of injection molding systems suits manufacturers serving multiple brand clients with different SKUs, where flexibility of allocation across presses is more valuable than raw throughput maximization.\n<h4>Expanding Capacity with Extrusion Equipment<\/h4>\nExtrusion capacity scales by adding parallel lines \u2014 each line is a self-contained production unit that can run different tube dimensions or material formulations independently. This parallel architecture suits large-volume manufacturers and contract packers with consistent demand for specific tube specifications. The risk in scaling extrusion is over-investment in single-specification capacity: a line optimized for 35mm 5-layer LDPE\/EVOH tubes has limited flexibility for a sudden shift to 22mm 3-layer tubes \u2014 requiring die head changes, screw speed recalibration, and potentially different extruder barrel configuration.\n<h3>Downtime and Maintenance Impact on Throughput<\/h3>\n<h4>Scheduled Maintenance Requirements for Each Method<\/h4>\nInjection molding presses require <strong>quarterly lubrication of tie bars, toggle joints, and injection unit components<\/strong>, with annual full overhaul of hydraulic systems (where applicable) and electrical control validation. Mold tools require separate preventive maintenance programs: quarterly polishing of cavity surfaces, inspection of ejector pins, and verification of cooling channel flow rates. Extrusion lines require daily inspection of die face and melt temperature profiles, weekly screw and barrel dimensional checks, and quarterly cleaning of die head flow channels. Both systems, when maintained on schedule, achieve <strong>OEE (Overall Equipment Effectiveness) of 85\u201392%<\/strong> \u2014 falling to 65\u201375% in facilities with deferred maintenance programs.\n<h4>Unplanned Downtime and Troubleshooting Protocols<\/h4>\nThe most common unplanned downtime events on injection molding lines are mold-related: <strong>ejector pin breakage, cavity scoring, cooling channel blockage, and parting line flash<\/strong>. Typical resolution times range from 30 minutes (ejector pin replacement) to 72+ hours (mold removal, repair, and reinstallation). On extrusion lines, unplanned downtime most commonly results from <strong>material degradation events (burnt material blocking die channels), haul-off drive failures, and cooling system temperature excursions<\/strong>. A blocked die head requiring full disassembly and cleaning represents 4\u201312 hours of downtime \u2014 a significant production impact at high-volume output rates.\n\n<!-- ============ PRODUCT QUALITY ============ -->\n<h2>Product Quality and Material Performance Comparison<\/h2>\n<h3>Wall Thickness Uniformity and Consistency<\/h3>\n<h4>Injection Molding Precision Standards<\/h4>\nFor tube shoulder components produced by injection molding, wall thickness tolerance of <strong>\u00b10.05mm to \u00b10.10mm<\/strong> is achievable on well-maintained tooling with consistent melt temperature and injection pressure control. This level of precision is critical for orifice dimensions (which determine product dispensing rate) and thread geometries (which determine cap sealing integrity). A pharmaceutical client whose product label states &#8220;apply 1cm of cream&#8221; depends on orifice diameter consistency within tenths of a millimeter \u2014 a specification that injection molding can meet reliably and injection-molded components can document in batch records.\n<h4>Extrusion Accuracy and Tolerance Specifications<\/h4>\nModern cosmetic tube extrusion lines with laser diameter gauging maintain external diameter tolerance of <strong>\u00b10.15mm to \u00b10.25mm<\/strong> and wall thickness uniformity of <strong>\u00b10.02\u20130.05mm<\/strong> under stable operating conditions. The critical quality parameter in extrusion is <strong>eccentricity<\/strong> \u2014 the degree to which the tube wall is thicker on one side than the other, resulting from die mandrel misalignment. Eccentricity above 10\u201315% creates weak spots that fail during squeeze testing and can cause tube splitting at retail. Spiral mandrel die designs and real-time wall thickness monitoring are the principal technical defenses against this failure mode.\n\n<a data-flickr-embed=\"true\" href=\"https:\/\/www.flickr.com\/photos\/204745097@N06\/55367565491\/in\/dateposted-public\/\" title=\"Displaying samples matte black toothpaste tube, paper-based cream tube, and glossy cosmetic tube\"><img decoding=\"async\" src=\"https:\/\/live.staticflickr.com\/65535\/55367565491_d8003e5e4b_b.jpg\" width=\"1024\" height=\"765\" alt=\"Displaying samples matte black toothpaste tube, paper-based cream tube, and glossy cosmetic tube\"\/><\/a><script async src=\"\/\/embedr.flickr.com\/assets\/client-code.js\" charset=\"utf-8\"><\/script> \n<p class=\"article-img-caption\">Quality control in tube manufacturing \u2014 particularly for pharmaceutical applications \u2014 demands dimensional verification, barrier integrity testing, and in-process statistical monitoring. The method chosen (injection vs. extrusion) determines which parameters require the most intensive control effort.<\/p>\n\n<h3>Aesthetic Qualities and Surface Finish<\/h3>\n<h4>Color Matching and Pigment Distribution<\/h4>\nInjection molding achieves uniform pigment distribution through the shear mixing action of the reciprocating screw \u2014 provided that masterbatch concentration and melt temperature are controlled within specification. <strong>Color consistency between shots<\/strong> is typically excellent on stable, well-maintained injection presses: Delta-E (color difference) values of 0.5\u20131.5 are achievable across a production run. Extrusion achieves good color consistency on the tube body but is more sensitive to masterbatch feed rate variation \u2014 a fluctuation of even 0.1% in pigment concentration at a high-speed line can produce visible color banding visible under fluorescent retail lighting.\n<h4>Surface Defects and Quality Control Measures<\/h4>\nCommon surface defects in injection molding include <strong>sink marks<\/strong> (depressions caused by material shrinkage away from the mold surface), <strong>weld lines<\/strong> (visible lines where two melt flow fronts meet), and <strong>gate marks<\/strong> (witness marks at the injection point). In extrusion, the primary aesthetic defects are <strong>die lines<\/strong> (longitudinal streaks caused by die damage or contamination), <strong>gels<\/strong> (unmelted material particles visible as specks in the tube wall), and <strong>surface roughness<\/strong> (caused by material degradation or excessively high output speeds). Both processes benefit from <strong>automated camera inspection systems<\/strong> that detect these defects at line speed, far exceeding what manual inspection can achieve.\n<h3>Structural Integrity and Durability Testing<\/h3>\n<h4>Pressure Resistance and Burst Strength Metrics<\/h4>\nCosmetic and pharmaceutical tube burst strength testing typically measures the internal pressure at which the tube body splits or the seal fails. Well-produced <strong>LDPE extrusion tubes (0.4mm wall thickness)<\/strong> routinely withstand 3\u20136 bar of internal pressure \u2014 well above the 0.5\u20131.5 bar generated during normal consumer squeeze use. Injection-molded tube shoulders must withstand both the squeeze stress transmitted through the body-shoulder joint and direct cap application torque. <strong>Joint integrity between the extruded body and injection-molded shoulder is itself a critical quality parameter<\/strong> \u2014 failure at this bond is more common than either component failing independently, and is managed through controlled heading machine temperature and pressure settings.\n<h4>Shelf-Life Performance and Material Degradation<\/h4>\nFor products with active pharmaceutical or cosmetic ingredients susceptible to oxygen degradation (vitamin C serums, retinol formulations, antibiotic creams), <strong>oxygen transmission rate (OTR) through the tube wall is the primary shelf-life determinant<\/strong>. Single-layer LDPE tubes have OTR values of 1,500\u20133,000 cm\u00b3\/m\u00b2\/day\u00b7bar \u2014 adequate for most cosmetics but insufficient for oxidation-sensitive pharmaceuticals. 5-layer co-extruded tubes with EVOH barrier layers achieve OTR values of <strong>0.1\u20135.0 cm\u00b3\/m\u00b2\/day\u00b7bar<\/strong> \u2014 a 300\u201330,000\u00d7 improvement that can extend pharmaceutical product shelf life from 12 months to 24\u201336 months. This barrier performance is the technical justification for the premium pricing of multi-layer extruded tube construction.\n\n<!-- ============ BEST-USE SCENARIOS ============ -->\n<h2>Best-Use Scenarios: Matching Method to Your Needs<\/h2>\n<h3>When Injection Molding Is Your Optimal Choice<\/h3>\n<h4>Complex Geometries and Intricate Design Requirements<\/h4>\nInjection molding is unequivocally the right choice when your product&#8217;s competitive positioning depends on <strong>distinctive, complex packaging geometry<\/strong>. If your brief includes an asymmetric flip-top cap that snaps precisely, an oval tube shoulder with embossed branding, a tapered nozzle with a precision-controlled orifice diameter, or a child-resistant closure mechanism integrated into the tube head \u2014 injection molding is the only process that delivers these features within a manufacturable cost structure. Luxury fragrance brands, medical device companies requiring precise drug delivery from topical tubes, and dental product manufacturers with precision applicator requirements all fit this profile.\n<h4>Small to Medium Production Volumes with Premium Positioning<\/h4>\nAt volumes of <strong>100,000\u2013500,000 tube shoulders annually<\/strong>, injection molding&#8217;s tooling cost amortizes to a manageable per-unit level while its quality and design advantages are fully realized. A dermatology brand producing 150,000 units per year of a prescription scar treatment cream \u2014 sold through pharmacies at premium pricing \u2014 gains more from injection molding&#8217;s dimensional precision and design customization than from extrusion&#8217;s throughput speed. The higher per-unit cost of injection molding is absorbed by the premium retail price, and the brand&#8217;s technical differentiation is protected by mold tooling that competitors cannot immediately replicate.\n<h3>When Extrusion Manufacturing Excels<\/h3>\n<h4>High-Volume Production and Mass-Market Applications<\/h4>\nThe economics of extrusion become dominant at <strong>1,000,000+ tube bodies annually<\/strong>. A major toothpaste brand producing 50 million tubes per year across five SKUs operates extrusion lines continuously \u2014 the per-unit tube body cost at this scale, including energy, labor, and amortized tooling, drops to <strong>$0.04\u2013$0.10 per tube body<\/strong>, a cost structure that injection molding cannot approach. Sunscreen, body lotion, shampoo-in-tube, hand cream, and over-the-counter ointment categories all operate in this volume regime and depend on extrusion economics to maintain retail price competitiveness.\n<h4>Standard Tube Designs with Quick Market Entry<\/h4>\nExtrusion&#8217;s shorter tooling lead time (6\u201310 weeks vs. 8\u201316 weeks for injection molds) and lower die cost make it the preferred route for <strong>time-sensitive product launches<\/strong> where standard circular tube designs are acceptable. A new brand launching a white-label sunscreen for a retail chain with a 90-day lead time requirement, or a contract manufacturer responding to a spot order for 500,000 pharmaceutical cream tubes, turns to extrusion as the only commercially viable option within the given timeline.\n<div class=\"method-card-grid\">\n<div class=\"method-card injection\">\n<h4>\ud83d\udd35 Choose Injection Molding When:<\/h4>\n<ul>\n \t<li>Your tube shoulder requires complex 3D geometry, integrated closures, or precision orifice control<\/li>\n \t<li>Annual volumes are below 500,000 units and design differentiation justifies tooling investment<\/li>\n \t<li>You serve premium cosmetic, specialty pharmaceutical, or dental product markets<\/li>\n \t<li>Fast SKU switching (2\u20134 hour mold changes) is operationally critical for your order profile<\/li>\n \t<li>Regulatory documentation of dimensional consistency is required per your quality system<\/li>\n<\/ul>\n<\/div>\n<div class=\"method-card extrusion\">\n<h4>\ud83d\udfe2 Choose Extrusion When:<\/h4>\n<ul>\n \t<li>Annual volumes exceed 500,000\u20131,000,000 tube bodies and cost-per-unit is the primary metric<\/li>\n \t<li>Your tube design is rotationally symmetric and standard diameters (16\u201360mm) are acceptable<\/li>\n \t<li>Barrier performance (EVOH multi-layer) is required for oxidation-sensitive formulations<\/li>\n \t<li>Time-to-market pressure makes 6\u201310 week die lead times preferable to 8\u201316 week mold cycles<\/li>\n \t<li>Continuous 24-hour production schedules can be maintained to maximize line utilization<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<h3>Hybrid Approaches and Combination Strategies<\/h3>\n<h4>Using Both Methods for Different Product Lines<\/h4>\nThe most sophisticated tube manufacturers use both processes simultaneously \u2014 <strong>extrusion for tube body production and injection molding for tube shoulder\/head components<\/strong> \u2014 within the same production ecosystem. This is, in fact, the standard architecture of the global soft tube manufacturing industry. Companies like <a href=\"https:\/\/miyodamachine.com\/fr\/\" target=\"_blank\" rel=\"noopener\">Miyoda Packaging Machinery<\/a> build complete integrated production lines that combine tube extrusion machines with tube heading and shoulder machines (which use injection molding to form the shoulder), plus downstream printing, filling, and capping equipment \u2014 precisely because neither process alone is sufficient to produce a complete, finished soft tube.\n<h4>Sequential Processing for Enhanced Results<\/h4>\nBeyond the standard extrusion-then-injection-heading sequence, some advanced manufacturers use <strong>sequential co-extrusion with in-line compression molding<\/strong> for tube heads \u2014 forming the shoulder from a slug of extruded material that is then compressed into shape rather than injection-molded from separate pellets. This approach reduces material transitions and can improve body-to-shoulder bond integrity. It&#8217;s particularly relevant for <a href=\"https:\/\/www.fda.gov\/media\/70788\/download\" target=\"_blank\" rel=\"noopener\">FDA-compliant pharmaceutical tube packaging<\/a> where process simplification reduces validation scope and regulatory documentation burden.\n\n<!-- ============ MATERIAL COMPATIBILITY ============ -->\n<h2>Material Compatibility and Formulation Considerations<\/h2>\n<h3>Thermoplastic Materials Suited for Each Method<\/h3>\n<h4>Polyethylene (PE) and Polypropylene (PP) Performance<\/h4>\nLDPE (Low-Density Polyethylene) is the dominant material for extruded soft tube bodies \u2014 its flexibility, chemical inertness, and compatibility with a wide range of cosmetic and pharmaceutical formulations make it the industry default. HDPE is used for tube shoulders and caps (injection molded) where greater stiffness and snap-fit integrity are needed. PP (Polypropylene) offers higher temperature resistance and chemical compatibility for aggressive formulations (high-alcohol toners, medicated creams with polar solvents) but is somewhat less flexible than LDPE, making it less ideal for tube bodies that must flex repeatedly during dispensing. <a href=\"https:\/\/www.xometry.com\/resources\/injection-molding\/injection-molding-vs.-extrusion\/\" target=\"_blank\" rel=\"noopener\">Processing parameters differ significantly between these materials<\/a> \u2014 LDPE extrudes at 160\u2013220\u00b0C while PP requires 220\u2013260\u00b0C, influencing both energy cost and equipment specification.\n<h4>Specialized Polymers and Barrier Material Options<\/h4>\nEVOH (Ethylene Vinyl Alcohol) is the barrier layer of choice in multi-layer co-extruded tubes \u2014 offering oxygen transmission rates 1,000\u201310,000\u00d7 lower than LDPE alone. Its limitation is moisture sensitivity: EVOH&#8217;s barrier performance degrades if it absorbs water, which is why it&#8217;s always sandwiched between LDPE layers in tube construction (the 5-layer LDPE\/TIE\/EVOH\/TIE\/LDPE architecture). TIE resins \u2014 adhesive polymers that bond incompatible materials like LDPE and EVOH \u2014 are the invisible heroes of multi-layer tube technology. Selecting the correct TIE resin for a given EVOH\/PE combination is a technical specification that directly impacts inter-layer adhesion strength and thus tube burst performance in drop tests and temperature cycling.\n<h3>Handling Sensitive Formulations<\/h3>\n<h4>Temperature Control During Processing<\/h4>\nMany pharmaceutical and premium cosmetic formulations contain active ingredients that are sensitive to heat exposure during tube manufacturing \u2014 specifically during the heading\/shoulder injection step, where temperatures of 180\u2013240\u00b0C are applied in close proximity to the extruded tube body. <strong>Managing heat exposure at the heading station is critical<\/strong> for formulations that will later contact retinol (which degrades above 25\u00b0C in solution), live probiotic cultures (killed above 40\u00b0C), or certain antibiotic compounds. The solution in commercial practice is maintaining an air gap between the hot shoulder injection zone and any product-contacting surfaces \u2014 the tube is empty during heading, so direct product exposure does not occur, but radiant heat must be managed to prevent tube body distortion.\n<h4>Shear Stress Management for Delicate Products<\/h4>\nThe high-shear environment of both injection molding (injection pressures of 700\u20131,500 bar) and extrusion (screw shear zones) can degrade shear-sensitive materials \u2014 including certain high-molecular-weight polymer additives, long-chain pigments, and some bio-based barrier polymers being developed for sustainable tube packaging. For these materials, <strong>single-screw extruder designs with optimized screw geometry and conservative output speeds are preferred<\/strong> over twin-screw systems (which generate higher shear energy). In injection molding, wider gates and runners that reduce flow velocity mitigate shear damage to sensitive material systems.\n\n<!-- ============ REGULATORY COMPLIANCE ============ -->\n<h2>Regulatory Compliance and Industry Standards<\/h2>\n<h3>FDA and International Certification Requirements<\/h3>\n<h4>Food Contact Surface Compliance for Both Methods<\/h4>\nBoth injection-molded and extruded tube components that will contact cosmetic or food products must comply with <strong>FDA 21 CFR \u00a7177 (Indirect Food Additives)<\/strong> and the equivalent <a href=\"https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/pharmaceutical-inspections-and-compliance\" target=\"_blank\" rel=\"noopener\">FDA regulations for food and drug contact materials<\/a>. In practice, this means using only resins, pigments, and additives that appear on the FDA&#8217;s positive lists for food-contact applications \u2014 and documenting their use in a material specification that suppliers must maintain and provide on request. EU cosmetic and pharmaceutical packaging must additionally comply with <strong>EC Regulation 10\/2011 (Plastic Food Contact Materials)<\/strong> et le <strong>European Pharmacopoeia<\/strong> requirements for pharmaceutical container materials.\n<h4>Pharmaceutical Packaging Standards and Documentation<\/h4>\nFor pharmaceutical tube packaging, the regulatory environment adds several layers beyond cosmetic requirements. Tube materials must be tested for <strong>extractables and leachables (E&amp;L)<\/strong> \u2014 the chemical compounds that can migrate from the tube wall into the product over its shelf life. This testing protocol, conducted by accredited third-party laboratories, can take <strong>6\u201312 months to complete<\/strong> and costs $15,000\u2013$50,000 per material system \u2014 a significant investment that is completed once per material formulation and then leveraged across all products using that tube construction. Both injection-molded and extruded components require E&amp;L testing; the multi-layer complexity of co-extruded tubes can expand the test scope significantly.\n\n<img decoding=\"async\" class=\"article-img\" src=\"https:\/\/images.pexels.com\/photos\/2280571\/pexels-photo-2280571.jpeg?w=1200&amp;q=80\" alt=\"Pharmaceutical packaging quality testing and regulatory compliance documentation in GMP laboratory\" \/>\n<p class=\"article-img-caption\">Pharmaceutical tube packaging must pass extractables and leachables testing, dimensional validation, and FDA\/EU GMP documentation requirements \u2014 processes that apply to both injection-molded and extruded components but with different scopes and timelines.<\/p>\n\n<h3>Quality Assurance and Testing Protocols<\/h3>\n<h4>Third-Party Testing and Certification Processes<\/h4>\nBeyond E&amp;L testing, commercial tube production for regulated markets requires <strong>ISO 15223 symbol compliance<\/strong> (for medical device adjacent applications), <strong>ISO 11607 packaging validation<\/strong> for sterile pharmaceutical products, and <strong>ASTM D4169<\/strong> distribution simulation testing (drop, vibration, and compression) to verify that tubes maintain integrity through the supply chain. Many major cosmetic retailers \u2014 including Sephora, Ulta, and major pharmacy chains \u2014 now require suppliers to provide <strong>REACH compliance declarations<\/strong> confirming that no substances of very high concern (SVHC) are present in tube materials at concentrations above 0.1% by weight.\n<h4>In-House Quality Control Implementation<\/h4>\nA robust in-house QC system for tube manufacturing \u2014 whether injection or extrusion-based \u2014 should include: <strong>incoming material certification review<\/strong> (verifying resin and masterbatch certificates of analysis against specification limits before use), <strong>first-article inspection (FAI)<\/strong> at the start of each production run (dimensional check of first 5\u201310 parts against the drawing), <strong>in-process statistical process control (SPC)<\/strong> with control charts tracking critical dimensions and weight, and <strong>final outgoing inspection<\/strong> per AQL (Acceptance Quality Level) sampling plans. Maintaining this QC infrastructure requires investment in measurement equipment \u2014 including coordinate measuring machines (CMMs) for injection-molded shoulders and laser gauges for extruded tube bodies \u2014 costing <strong>$20,000\u2013$80,000 in capital equipment<\/strong> for a fully equipped QC lab.\n\n<!-- ============ DECISION FRAMEWORK ============ -->\n<h2>Making Your Decision: A Practical Comparison Framework<\/h2>\n<h3>Evaluating Your Production Volume Requirements<\/h3>\n<h4>Volume Thresholds for Economic Viability<\/h4>\nThe economic logic of technology selection in tube manufacturing is most clearly expressed through volume thresholds. <strong>Below 100,000 units annually<\/strong>, neither injection molding nor full extrusion lines are truly economically optimized \u2014 at this scale, purchasing tube bodies from a tube supply specialist and focusing capital on filling and packaging equipment is often the smarter strategy. Between <strong>100,000 and 500,000 units<\/strong>, injection molding for shoulders combined with purchased tube bodies is the typical solution. Above <strong>500,000 units<\/strong>, investing in in-house extrusion capacity begins to show positive ROI, particularly if multiple SKUs can share a production line. Above <strong>2,000,000 units<\/strong>, dedicated extrusion lines running continuously are almost always the most cost-effective manufacturing configuration.\n<h4>Calculating Break-Even Points for Equipment Investment<\/h4>\nThe break-even calculation for tube manufacturing equipment compares the <strong>cost of purchasing finished tubes from external suppliers against the total cost of in-house production<\/strong>. A typical break-even analysis framework: if an external tube supplier charges $0.30 per tube body and your in-house extrusion cost (capital amortized over 7 years + energy + labor + materials) is $0.12 per tube body, you save $0.18 per unit. At 1,000,000 units per year, that saving of $180,000 annually justifies a capital investment of approximately $900,000\u2013$1,260,000 (5\u20137 year payback). The <a href=\"https:\/\/miyodamachine.com\/fr\/automatic-vs-semi-automatic-cosmetic-tube-filling-machine\/\" target=\"_blank\" rel=\"noopener\">choice of automation level in your tube filling line<\/a> interacts with this calculation \u2014 a fully automatic line maximizes labor efficiency and strengthens the in-house production business case.\n<h3>Assessing Your Design and Customization Needs<\/h3>\n<h4>Complexity Scoring System for Your Tube Design<\/h4>\n<div class=\"decision-matrix\">\n<h3>\ud83c\udfaf Quick Design Complexity Scoring Guide<\/h3>\n<p style=\"font-size: 0.92em; color: #555; margin-bottom: 16px;\">Score your tube design against the criteria below. A total score of <strong>12+<\/strong> strongly favors injection molding for the shoulder component; scores of <strong>6 or below<\/strong> indicate extrusion is likely sufficient.<\/p>\n\n<div class=\"scoring-row\" style=\"font-weight: bold; padding-bottom: 6px;\"><span class=\"score-label score-header\">Design Feature<\/span>\n<span class=\"score-injection score-header\">Injection Score<\/span>\n<span class=\"score-extrusion score-header\">Extrusion Score<\/span><\/div>\n<div class=\"scoring-row\"><span class=\"score-label\">Non-circular shoulder\/tube cross-section (oval, rectangular)<\/span>\n<span class=\"score-injection\">+4<\/span>\n<span class=\"score-extrusion\">Not possible<\/span><\/div>\n<div class=\"scoring-row\"><span class=\"score-label\">Integrated flip-top, tamper-evident, or child-resistant closure<\/span>\n<span class=\"score-injection\">+4<\/span>\n<span class=\"score-extrusion\">+0<\/span><\/div>\n<div class=\"scoring-row\"><span class=\"score-label\">Precision orifice diameter tolerance \u2264 \u00b10.1mm<\/span>\n<span class=\"score-injection\">+3<\/span>\n<span class=\"score-extrusion\">+1<\/span><\/div>\n<div class=\"scoring-row\"><span class=\"score-label\">Embossed or debossed surface texture on shoulder<\/span>\n<span class=\"score-injection\">+3<\/span>\n<span class=\"score-extrusion\">+0<\/span><\/div>\n<div class=\"scoring-row\"><span class=\"score-label\">Standard circular cross-section, round shoulder<\/span>\n<span class=\"score-injection\">+1<\/span>\n<span class=\"score-extrusion\">+3<\/span><\/div>\n<div class=\"scoring-row\"><span class=\"score-label\">Multi-layer barrier performance required (EVOH)<\/span>\n<span class=\"score-injection\">+1<\/span>\n<span class=\"score-extrusion\">+4<\/span><\/div>\n<div class=\"scoring-row\"><span class=\"score-label\">Volume above 1,000,000 units\/year<\/span>\n<span class=\"score-injection\">+1<\/span>\n<span class=\"score-extrusion\">+4<\/span><\/div>\n<\/div>\n<h4>Flexibility Requirements for Future Product Lines<\/h4>\nOne underappreciated dimension of the injection vs. extrusion decision is <strong>future flexibility<\/strong>. A tube manufacturer who today produces a single SKU at 800,000 units per year may serve six different brand clients at varying volumes within three years. Injection molding infrastructure scales well to this multi-SKU, variable-volume model \u2014 new molds can be added for new SKU designs without modifying the machine park, and presses can be shared across multiple tooling sets. Extrusion infrastructure is more efficient but less flexible \u2014 each new tube specification may require die head changes or even a dedicated line.\n<h3>Analyzing Your Market Timeline and Launch Pressures<\/h3>\n<h4>Time-to-Market Considerations for Each Method<\/h4>\nIn product categories where speed-to-shelf determines market capture \u2014 seasonal beauty products, limited edition launches, pharmaceutical products approaching patent cliff windows \u2014 the manufacturing method&#8217;s tooling lead time can be a competitive bottleneck. Extrusion die tooling at <strong>6\u201310 weeks<\/strong> versus injection mold development at <strong>8\u201316 weeks<\/strong> creates a meaningful window: a brand that chooses extrusion-compatible tube designs reduces its time-to-market by 4\u20136 weeks versus a comparable injection-molded tube design. In a market where a 4-week earlier launch translates to 8% more category sales in a seasonal window, that manufacturing choice has revenue implications far beyond the tooling cost differential.\n<h4>Competitive Advantage Through Manufacturing Selection<\/h4>\nThe most durable competitive advantages in tube manufacturing come from <strong>proprietary tooling and process knowledge<\/strong> \u2014 not just equipment ownership. A manufacturer who has invested $200,000 in custom injection molds for a distinctive tube shoulder design that the brand&#8217;s customers associate with premium quality has built a barrier that a competitor cannot easily cross, even if they own identical machines. Similarly, a manufacturer who has optimized a 5-layer EVOH co-extrusion process for 24-month stability of oxidation-sensitive pharmaceutical formulations owns process knowledge \u2014 in die geometry, temperature profiles, and layer ratios \u2014 that is not transferable without years of development experience.\n\n<!-- ============ IMPLEMENTATION STRATEGY ============ -->\n<h2>Implementation Strategy and Next Steps<\/h2>\n<h3>Vendor Selection and Equipment Sourcing<\/h3>\n<h4>Evaluating Machine Manufacturers and Suppliers<\/h4>\nWhen evaluating tube production machinery suppliers, four criteria matter above all others. <strong>First, application specificity:<\/strong> a supplier whose reference customer list includes cosmetic and pharmaceutical tube producers in your volume range is worth more than one with broad plastics industry experience but no tube-specific track record. <strong>Second, spare parts and service response:<\/strong> a machine without accessible spare parts or within-48-hour service response is an operational liability in a continuous production environment. <strong>Third, process documentation and training:<\/strong> the supplier should provide comprehensive operator training, maintenance manuals, and process setup guides in your team&#8217;s language. <strong>Fourth, integration capability:<\/strong> a tube production line is not a single machine \u2014 it&#8217;s a system of extruder, die head, cooling, cutting, heading machine, printer, filler, capper, and inspection equipment. Suppliers who can integrate these stages \u2014 such as <a href=\"https:\/\/miyodamachine.com\/fr\/product\/\" target=\"_blank\" rel=\"noopener\">Miyoda Packaging Machinery&#8217;s complete tube production line offering<\/a> \u2014 reduce integration risk, responsibility gaps between vendors, and system commissioning time.\n<h4>Negotiating Terms and Support Agreements<\/h4>\nEquipment purchase agreements for tube production lines should explicitly address: <strong>acceptance testing criteria<\/strong> (the specific production rates, part dimensions, and reject rates the machine must achieve before final payment is released), <strong>warranty scope<\/strong> (which components are covered, for how long, and who bears the cost of technician travel for warranty repairs), <strong>spare parts provisions<\/strong> (a starter kit of critical wear parts should be included in the purchase price), and <strong>training commitment<\/strong> (on-site operator and maintenance technician training at installation, plus remote support access for the first year of production). Service Level Agreements (SLAs) committing the supplier to <strong>24-hour response time for critical downtime events<\/strong> are standard expectations for pharmaceutical-grade production environments.\n<h3>Facility Planning and Installation Requirements<\/h3>\n<h4>Space Allocation and Utility Infrastructure<\/h4>\nA complete tube extrusion line (extruder, cooling tank, haul-off, cutter) occupies approximately <strong>15\u201325 linear meters of floor space<\/strong> and requires ceiling height of at least 3.5 meters for die head maintenance access. Injection molding presses for tube shoulder production have a smaller footprint (3\u20136 meters per press) but require adjacent mold storage, tool change areas, and temperature control equipment space. Utility infrastructure for a tube production facility includes: <strong>3-phase power supply<\/strong> (typical connected loads of 50\u2013150 kW per line), <strong>compressed air<\/strong> (6\u20138 bar, 200\u2013500 liters per minute per line for pneumatic actuators and cooling), <strong>chilled cooling water<\/strong> (for mold temperature control and extrusion cooling baths), and <strong>climate-controlled production environment<\/strong> (18\u201324\u00b0C) to maintain material consistency in humidity-sensitive barrier layer applications.\n<h4>Workforce Training and Operational Setup<\/h4>\nRealistic operational setup timelines for a new tube production facility: <strong>Equipment installation and commissioning: 4\u20138 weeks<\/strong> after machine delivery (longer for multi-line, multi-stage systems). <strong>Process development and optimization: 4\u201312 weeks<\/strong> to dial in extrusion parameters (temperature profiles, line speed, layer ratios) or injection parameters (injection pressure, cooling time, mold temperature) for specific tube specifications and materials. <strong>First production validation: 2\u20134 weeks<\/strong> of test production against quality specifications before the first commercial batch is released. <strong>Full operational competency: 3\u20136 months<\/strong> from first commercial production for operators to achieve consistent independent performance without supervisor guidance.\n<h3>Pilot Production and Validation Process<\/h3>\n<h4>Running Test Batches and Quality Verification<\/h4>\nPilot production for a new tube specification should produce a minimum of <strong>500\u20132,000 units (injection molding) or 50\u2013100 meters of tube body (extrusion)<\/strong> at commercial machine settings before final approval. These samples undergo the full battery of qualification testing: dimensional measurement against drawing tolerances, visual inspection per AQL 1.0 sampling plan, barrier property testing (OTR for EVOH tubes), burst strength and drop tests, and for pharmaceutical applications, extractables screening. The data from pilot production defines the <strong>Design of Experiment (DOE) space<\/strong> that will govern normal process operation \u2014 and establishes the process parameter ranges that QC personnel will monitor during commercial production.\n<h4>Scaling to Full Commercial Production<\/h4>\nThe transition from pilot to full commercial production should be managed through a <strong>scale-up protocol<\/strong> that increases production speed in defined steps (50% \u2192 75% \u2192 100% of target speed) with quality verification at each step. On extrusion lines, increasing line speed changes the residence time in the cooling bath and the tension on the haul-off \u2014 both of which affect wall thickness and eccentricity and must be revalidated at each speed step. On injection molding lines, increasing shot frequency reduces the effective cooling time per cycle, which can increase sink mark incidence and dimensional variation in shoulder components. Both effects are predictable and manageable with proper transition protocols.\n\n<!-- ============ CONCLUSION ============ -->\n<h2>Conclusion: Aligning Manufacturing Method with Business Goals<\/h2>\nThe injection vs. extrusion decision for soft tube manufacturing is not a universal answer \u2014 it&#8217;s an <strong>analytical exercise specific to your product, your volume, your market, and your timeline<\/strong>. In reality, the global tube manufacturing industry has long since concluded that both methods are necessary: extrusion for tube bodies, injection molding for tube shoulders and heads. The strategic question is not which process to use, but <strong>which combination of capability, automation level, and integration depth makes commercial sense for your specific situation today \u2014 and leaves you room to scale efficiently in three years.<\/strong>\n\nA brand producing 200,000 premium skincare tubes per year needs a different equipment configuration than a contract manufacturer filling 10 million toothpaste tubes annually. A pharmaceutical company with strict FDA process validation requirements needs a different approach to machine selection than a cosmetic startup testing a new formulation at 50,000 units. <strong>Getting this decision right from the start \u2014 rather than adjusting it mid-production \u2014 is what separates businesses that scale smoothly from those that reinvest in new equipment two years after their initial purchase.<\/strong>\n\nThe most valuable step you can take before committing capital is to benchmark your specific tube design, target volume, and quality specifications against the proven performance of both process types \u2014 ideally by reviewing data from a machinery partner with experience in both technologies. <a href=\"https:\/\/miyodamachine.com\/fr\/tube-filling-and-sealing-machine-guide-cosmetics-pharmaceuticals\/\" target=\"_blank\" rel=\"noopener\">Understanding the complete tube production ecosystem<\/a> \u2014 from raw material through extrusion, heading, printing, filling, and sealing \u2014 positions you to make that investment with confidence and build a production operation that serves your market position for years to come.\n\n<!-- ============ FAQ SECTION ============ -->\n<div class=\"faq-section\">\n<h2>Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<div class=\"faq-item\">\n<h4>FAQ 1: What is the typical lifespan of injection molds versus extrusion dies in tube production?<\/h4>\nInjection molds for tube shoulder production, manufactured from hardened tool steel (H13 or P20 grade), typically achieve <strong>500,000 to 1,000,000+ production cycles<\/strong> with a proper preventive maintenance program \u2014 including periodic cavity polishing, ejector pin inspection, and cooling channel cleaning. Extrusion die heads, being continuous-use tools rather than cycle-based, are better measured by years of service: a well-maintained spiral mandrel multi-layer die head lasts <strong>5\u201310 years<\/strong> under normal cosmetic tube production conditions. Injection molds represent a higher upfront cost ($15,000\u2013$80,000) but can be re-steeled or refurbished when worn, often extending their service life by 50% at 20\u201330% of original cost. Die head maintenance costs are lower per year but more sensitive to material contamination events that can necessitate expensive tip replacement or precision rework.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 2: Can I switch between injection and extrusion methods if my business needs change?<\/h4>\nYes \u2014 but the transition requires investment in different equipment and tooling, not just process adjustments. Many successful tube manufacturers deliberately operate both systems simultaneously, using <strong>injection-molded shoulder components on extruded tube bodies<\/strong> as standard practice. If you mean switching from purchasing externally manufactured tubes (either type) to in-house production, the transition timeline is typically 6\u201312 months from equipment order to stable commercial production. Businesses that begin with extrusion and later add injection molding capacity for premium product lines follow a common growth pattern in the cosmetic tube manufacturing industry \u2014 and equipment suppliers experienced in complete tube production lines can help structure this expansion without creating incompatible equipment ecosystems.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 3: Which method produces tubes with better barrier properties for pharmaceutical products?<\/h4>\nFor pharmaceutical tube packaging where barrier performance is critical, <strong>multi-layer co-extrusion with EVOH barrier layers<\/strong> delivers the best results \u2014 achieving oxygen transmission rates (OTR) of 0.1\u20135.0 cm\u00b3\/m\u00b2\/day\u00b7bar, compared to 1,500\u20133,000 cm\u00b3\/m\u00b2\/day\u00b7bar for single-layer LDPE tubes. This makes co-extrusion the method of choice for oxidation-sensitive pharmaceutical formulations including antibiotic creams, retinoid-based treatments, and certain antifungal preparations. Injection molding alone (for tube shoulders) offers excellent dimensional precision for orifice control \u2014 critical for topical pharmaceutical dosing accuracy \u2014 but does not inherently provide barrier function to the tube body. The best pharmaceutical tube solution combines both: a 5-layer EVOH co-extruded tube body with a precision injection-molded shoulder engineered to the validated orifice specification.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 4: What production volumes justify investing in each system?<\/h4>\nThe volume thresholds for economic viability in tube production are: <strong>Injection molding for tube shoulders becomes viable at 100,000\u2013200,000 units annually<\/strong>, assuming a 2\u20134 cavity mold and standard tube head design. At this volume, the mold cost amortizes to $0.075\u2013$0.150 per shoulder over a 500,000-cycle tool life. <strong>In-house extrusion for tube bodies becomes economically attractive above 500,000 units annually<\/strong>, where the capital cost of a complete extrusion line is offset by savings versus purchasing tube bodies from an external supplier. At 1,000,000+ units per year, extrusion produces the decisive per-unit cost advantage \u2014 <strong>$0.08\u2013$0.18 per tube body versus $0.20\u2013$0.40 for smaller extrusion volumes<\/strong> \u2014 that makes it the standard choice for all major commercial tube producers worldwide.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 5: How do material costs compare between injection and extrusion manufacturing?<\/h4>\nMaterial costs per tube are influenced by three variables: raw material price, material waste rate, and part weight. <strong>Extrusion generates 2\u20135% material waste<\/strong> (from startup scrap and trim) versus <strong>5\u201310% for injection molding<\/strong> (from runners, sprues, and rejected parts). On a mass basis, extrusion is therefore 3\u20138% more material-efficient. However, this advantage is partially offset by injection molding&#8217;s superior part consistency \u2014 which typically reduces downstream rejection rates (tubes that fail functional testing after heading, printing, or filling) to <strong>0.1\u20130.5%<\/strong> versus <strong>0.3\u20131.0%<\/strong> for extrusion at comparable quality control investment levels. Net material efficiency, accounting for both upstream waste and downstream rejections, often yields comparable total material costs between the two methods at similar production scales.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 6: Can both methods produce the same tube designs and specifications?<\/h4>\nFor standard circular tube designs with simple round shoulders and straight orifice tips \u2014 which represent the majority of toothpaste, hand cream, and pharmaceutical ointment packaging worldwide \u2014 both methods can produce fully functional, commercially acceptable results. <strong>The design space where injection molding has no extrusion equivalent<\/strong> includes: oval and flat tube shoulder cross-sections, integrated flip-top and snap-shut closures molded into the shoulder, precisely controlled orifice diameters below 3mm (for pharmaceutical dosing applications), and embossed or debossed branding elements on the shoulder body. If your tube design includes any of these features, injection molding is not optional \u2014 it&#8217;s technically necessary. For everything else, the choice is an economic and lead time decision rather than a technical one.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 7: What is the average lead time for developing production-ready tube manufacturing equipment?<\/h4>\nTotal lead time from purchase order to first commercial production involves two sequential phases: equipment manufacturing and delivery (typically <strong>10\u201320 weeks<\/strong> for standard production line configurations, longer for highly customized systems), followed by installation, commissioning, and process development (<strong>4\u201312 weeks<\/strong> depending on process complexity and operator experience). Tooling development runs in parallel with equipment manufacturing where possible: injection molds require <strong>8\u201316 weeks from design freeze to first-article sample<\/strong>, while extrusion die heads require <strong>6\u201312 weeks<\/strong>. Total time from purchase order to first commercial production on a new tube line therefore ranges from <strong>20\u201336 weeks (5\u20139 months)<\/strong> \u2014 a planning horizon that most new market entrants significantly underestimate.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 8: Which tube manufacturing method is more environmentally sustainable?<\/h4>\nExtrusion holds an inherent sustainability advantage in material efficiency \u2014 <strong>2\u20135% scrap versus 5\u201310% for injection molding<\/strong> \u2014 reducing raw material consumption and landfill waste at equivalent output volumes. Additionally, modern co-extrusion lines can process <strong>post-consumer recycled (PCR) content at 25\u2013100% levels<\/strong>, enabling circular economy commitments that major cosmetic brands are now contractually requiring of their tube suppliers. Injection molding is less compatible with high PCR content due to the tighter processing windows required for precision dimensional control. On energy consumption, extrusion&#8217;s continuous operation offers better energy efficiency per unit at high volumes. The most sustainable solution overall combines <strong>PCR-capable extrusion for tube bodies with energy-efficient servo-electric injection presses for shoulders<\/strong>, minimizing material waste while meeting design and regulatory requirements.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 9: How does production flexibility differ between injection molding and extrusion?<\/h4>\nInjection molding is the more flexible system for manufacturers serving <strong>multiple SKUs with varying volumes and design specifications<\/strong>. Mold changeovers on a well-organized injection press take <strong>2\u20134 hours<\/strong>, allowing a single machine to serve 3\u20134 different product designs in a working day. Extrusion die changes require <strong>4\u20138 hours<\/strong> of downtime, plus additional time to purge the previous material and stabilize the new process \u2014 making extrusion inherently suited to long, uninterrupted production runs of a single specification. For contract manufacturers whose business model involves serving 20+ brand clients with different tube designs, injection molding&#8217;s change flexibility is operationally essential. For dedicated tube suppliers producing 5\u201310 high-volume SKUs continuously, extrusion&#8217;s throughput advantage dominates.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 10: What are the typical energy costs for operating each system?<\/h4>\nInjection molding machines for tube shoulder production consume <strong>15\u201325 kW per operational cycle<\/strong>, with modern servo-electric machines at the lower end of this range. Extrusion lines run continuously at <strong>20\u201340 kW<\/strong> depending on number of extruder layers, output speed, and barrel heating zone configuration. At high production volumes (1M+ units\/year), extrusion&#8217;s continuous operation typically delivers <strong>15\u201325% better energy efficiency per unit produced<\/strong> compared to injection molding \u2014 because the thermal energy stored in the barrel system is utilized more efficiently across a continuous output stream than across discrete injection cycles with idle periods. Both technologies have benefited significantly from the shift to servo-electric drive systems over the past decade, reducing energy consumption by 20\u201335% versus equivalent hydraulic predecessors.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 11: Which method provides better options for adding features like applicators or caps?<\/h4>\nInjection molding is significantly more capable for <strong>integrated feature design<\/strong> \u2014 the ability to mold applicator tips, precision orifice geometries, hinge mechanisms, and snap-fit cap engagement features directly into the tube shoulder in a single cycle. A nasal pharmaceutical ointment tube with a curved applicator tip, a mascara-like brush applicator molded integral to the shoulder, or a spatula-tip dermatology product all require injection molding capabilities that extrusion cannot replicate. For standard caps (screw-on, flip-top), both tube types accept the same <strong>standardized cap tooling<\/strong> \u2014 caps are almost universally injection-molded components regardless of whether the tube body is extruded or the shoulder is injection-formed. <a href=\"https:\/\/miyodamachine.com\/es\/products\/tube-capping-machine\/\" target=\"_blank\" rel=\"noopener\">Automated tube capping machines<\/a> handle both cap types equally well.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 12: How do quality assurance protocols differ between injection and extrusion?<\/h4>\nInjection molding QA focuses on <strong>shot-to-shot consistency<\/strong> across a relatively small set of high-impact variables: injection pressure, melt temperature, cooling time, and clamping force. Statistical Process Control (SPC) on an injection press tracks 5\u20138 key parameters with tolerance windows of \u00b12\u20135%. Extrusion QA is fundamentally different \u2014 it requires <strong>continuous monitoring of a dynamic process<\/strong> with real-time adjustment capability. Key monitored parameters include die head pressure, melt temperature at each zone (typically 6\u201310 zones), line speed, haul-off tension, and external diameter (via laser gauging). A well-configured extrusion line with in-line gauging can detect wall thickness drift within seconds and automatically adjust die gap or line speed to correct it \u2014 a closed-loop capability that makes modern extrusion quality control more responsive, if also more technically demanding, than injection molding QC.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 13: What is the typical cost per unit for injection versus extrusion at different volumes?<\/h4>\nBased on commercial production data from the tube manufacturing industry, the per-unit cost benchmarks (tube body + shoulder component combined, excluding filling and decorating) are: <strong>At 100,000 units\/year:<\/strong> injection molding $0.15\u2013$0.35\/unit vs. extrusion $0.20\u2013$0.40\/unit (injection has the advantage at small volumes due to its lower machine capital cost relative to a full extrusion line). <strong>At 500,000 units\/year:<\/strong> costs converge to approximately $0.12\u2013$0.20\/unit for both methods. <strong>At 1,000,000 units\/year:<\/strong> injection $0.12\u2013$0.25\/unit vs. extrusion $0.08\u2013$0.18\/unit \u2014 extrusion&#8217;s advantage becomes clear and grows with scale. <strong>At 5,000,000 units\/year:<\/strong> extrusion tube body cost can fall below $0.06\/unit, a level injection molding cannot approach regardless of cavity count optimization.\n\n<\/div>\n<div class=\"faq-item\">\n<h4>FAQ 14: Can I produce cosmetic and pharmaceutical tubes on the same equipment?<\/h4>\nMechanically, yes \u2014 both extrusion lines and injection molding presses that are built to pharmaceutical material standards (food-grade resins, cleanroom-compatible designs) can physically produce tubes for both applications. The critical distinction is <strong>operational and regulatory, not mechanical<\/strong>. Pharmaceutical-grade production requires validated processes (IQ\/OQ\/PQ qualification), documented cleaning procedures between product types, batch records traceable to individual equipment operating parameters, and in many cases, <strong>dedicated equipment lines<\/strong> to eliminate cross-contamination risk between pharmaceutical and cosmetic products. Regulatory authorities including the FDA and EMA expect pharmaceutical tube manufacturers to demonstrate that cosmetic production activities do not compromise the quality, safety, or integrity of pharmaceutical packaging produced on adjacent equipment. If your business model includes both cosmetic and pharmaceutical clients, discuss equipment segregation strategy with your regulatory affairs team before finalizing equipment layout.\n\n<\/div>\n<\/div>\n<!-- ============ CTA SECTION ============ -->\n<div class=\"cta-section\">\n<h2>Ready to Build the Right Tube Production Line?<\/h2>\nWhether you&#8217;re evaluating your first tube manufacturing investment or optimizing an existing operation, the right equipment specification makes the difference between a production line that serves your market position for a decade and one that requires costly mid-cycle replacement. Our specialists at <strong>Miyoda Packaging Machinery<\/strong> work with cosmetic brands, pharmaceutical manufacturers, and tube machinery distributors worldwide to match production technology to real operational requirements \u2014 volume, design complexity, compliance environment, and growth trajectory included.\n\n<a class=\"cta-btn\" href=\"https:\/\/miyodamachine.com\/fr\/\" target=\"_blank\" rel=\"noopener\">Request Your Free Production Consultation \u2192<\/a>\n\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>The decision between injection molding and extrusion is one of the most consequential choices a tube manufacturer can make \u2014 and it&#8217;s rarely as simple as picking the faster or cheaper option. Your choice will determine not just your per-unit cost today, but your ability to launch new designs, scale volume, meet regulatory requirements, and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5021,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_titles_title":"Injection vs. Extrusion: Which Tube Method Wins?","_seopress_titles_desc":"Compare injection molding vs. extrusion for tube manufacturing: costs, speed, quality, and which method suits cosmetic or pharma production best.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"footnotes":""},"categories":[64,65,59],"tags":[],"class_list":["post-5019","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","category-tube-packaging-industry-trends-market-insights","category-news"],"_links":{"self":[{"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/posts\/5019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/comments?post=5019"}],"version-history":[{"count":4,"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/posts\/5019\/revisions"}],"predecessor-version":[{"id":5024,"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/posts\/5019\/revisions\/5024"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/media\/5021"}],"wp:attachment":[{"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/media?parent=5019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/categories?post=5019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/miyodamachine.com\/fr\/wp-json\/wp\/v2\/tags?post=5019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}